PHATHOM PHARMACEUTICALS INC's ticker is PHAT and the CUSIP is 71722W107. A total of 62 filers reported holding PHATHOM PHARMACEUTICALS INC in Q2 2020. The put-call ratio across all filers is - and the average weighting 1.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $96,556 | +1313.7% | 9,311 | +1852.0% | 0.00% | – |
| Q2 2023 | $6,830 | +56816.7% | 477 | -72.0% | 0.00% | – |
| Q1 2023 | $12 | +140.0% | 1,705 | +250.8% | 0.00% | – |
| Q4 2022 | $5 | -100.0% | 486 | -89.1% | 0.00% | -100.0% |
| Q3 2022 | $49,000 | +8.9% | 4,451 | -17.3% | 0.00% | 0.0% |
| Q2 2022 | $45,000 | -11.8% | 5,380 | +45.6% | 0.00% | – |
| Q1 2022 | $51,000 | +537.5% | 3,696 | +788.5% | 0.00% | – |
| Q4 2021 | $8,000 | -57.9% | 416 | -31.4% | 0.00% | – |
| Q3 2021 | $19,000 | -85.4% | 606 | -84.2% | 0.00% | -100.0% |
| Q2 2021 | $130,000 | +165.3% | 3,833 | +191.3% | 0.00% | +200.0% |
| Q1 2021 | $49,000 | -31.9% | 1,316 | -39.0% | 0.00% | -50.0% |
| Q4 2020 | $72,000 | -82.5% | 2,157 | -80.8% | 0.00% | -60.0% |
| Q3 2020 | $411,000 | +478.9% | 11,212 | +420.5% | 0.01% | +66.7% |
| Q2 2020 | $71,000 | – | 2,154 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Medicxi Ventures Management (Jersey) Ltd | 3,760,869 | $39,000,212 | 12.45% |
| Frazier Life Sciences Management, L.P. | 10,109,279 | $104,833,223 | 6.96% |
| Decheng Capital Management III (Cayman), LLC | 850,000 | $8,814,500 | 2.94% |
| Carlyle Group Inc. | 3,496,808 | $36,191,963 | 1.57% |
| Ghost Tree Capital, LLC | 395,000 | $4,096,150 | 1.35% |
| Newtyn Management, LLC | 500,000 | $5,185,000 | 1.28% |
| Altium Capital Management LP | 220,000 | $2,281,400 | 1.19% |
| StepStone Group LP | 422,085 | $4,377,021 | 0.98% |
| MPM BioImpact LLC | 347,332 | $3,601,833 | 0.96% |
| NEA Management Company, LLC | 1,276,595 | $12,238,290 | 0.94% |